Therapy of other viral infections: Herpes to hepatitis

Dermatologic Therapy

Volumn 17, Issue 6, 2004, Pages 465-490

  Chakrabarty, Arun ^a   Beutner, Karl ^a  

^a Solano Research   (United States)

Author keywords

Hepatitis; Herpes viruses; Measles; Parvovirus; Poxviruses; Rubella

Indexed keywords

ACICLOVIR; ADEFOVIR; ALITRETINOIN; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CAPSAICIN; CIDOFOVIR; CORTICOSTEROID; DEXAMETHASONE; FAMCICLOVIR; FOSCARNET; GABAPENTIN; GANCICLOVIR; IDOXURIDINE; IMMUNOGLOBULIN; LAMIVUDINE; MEASLES MUMPS RUBELLA VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEGINTERFERON ALPHA2A; PREDNISONE; RESIQUIMOD; RIBAVIRIN; RITUXIMAB; TENOFOVIR; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VIDARABINE; VIRUS VACCINE;

BURNING SENSATION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; EPSTEIN BARR VIRUS; ERYTHEMA INFECTIOSUM; FATIGUE; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; MEASLES; META ANALYSIS; MOLLUSCUM CONTAGIOSUM; MONKEYPOX; MUMPS; NAUSEA; NEUTROPENIA; NONHUMAN; POSTHERPETIC NEURALGIA; POXVIRUS INFECTION; REVIEW; RUBELLA; SIDE EFFECT; SMALLPOX; TANAPOX; VACCINIA; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS TRANSMISSION; VOMITING;

ANIMALS; ANTIVIRAL AGENTS; DIAGNOSIS, DIFFERENTIAL; HEPATITIS, VIRAL, HUMAN; HERPESVIRIDAE INFECTIONS; HUMANS; MEASLES; MUMPS; PARVOVIRIDAE INFECTIONS; POXVIRIDAE INFECTIONS; RUBELLA; SKIN DISEASES, VIRAL; VACCINATION;

EID: 10844270304     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1396-0296.2004.04049.x     Document Type: Review

References (220)

1. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003 October: 30 (10): 797-800.
2. Weymann G. Novel agents and strategies to treat herpes simplex virus infections. Expert Opin Invest Drugs 2003 February: 12 (2): 165-183.
3. King DH. History, pharmacokinetics, and pharmacology of acyclovir. J Am Acad Dermatol 1988 January: 18 (1 Part 2): 176-179.
4. Fletcher C, Bean B. Evaluation of oral acyclovir therapy. Drug Intell Clin Pharm 1985 July-August: 19 (7-8): 518-524.
5. Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis: a double-blind, placebo-controlled trial. Ann Intern Med 1993: 118: 268-272.
6. Spruance SL, Hamill ML, Hoge WS, et al. Acyclovir prevents reactivation of herpes labialis among skiers. JAMA 1989: 260 (11): 1597-1599.
7. Spruance SL, Stewart JCB, Rowe NH, et al. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990: 161 (2): 185-190.
8. Wilhelmus KR, Beck RW, Moke PS, et al. Acyclovir for the prevention of recurrent herpes simplex eye disease. N Engl J Med 1998: 339: 300-306.
9. Raborn GW, McGaw WT, Grace M, et al. Herpes labialis treatment with acyclovir 5% ointment. J Can Dent Assoc 1989: 55 (2): 135-137.
10. Spruance SL, Crumpacker CS, Schnipper LE, et al. Early patient initiated treatment of herpes labialis with topical 10% acyclovir. Antimicrobial Agents Chemother 1984: 25 (5): 533-555.
11. Spruance SL, Nett R, Marbury T, et al. Acyclovir cream for the treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother 2002: 46 (7): 2238-2243.
12. Spruance SL, Rea TL, Thoming C, et al. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA 1997: 277: 1374-1379.
13. Habbema L. n-Docasonal 10% cream in the treatment of recurrent herpes labialis: a randomized, double-blind, placebo-controlled study. Acta Derm Venereol 1996: 76: 479-481.
14. Mertz GJ. Management of genital herpes. Adv Exp Med Biol 1996: 394: 1-10.
15. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986: 314: 144-149.
16. Spruance SL, Jones TM, Blatter M, et al. High-dose, short duration, early valacyclovir therapy for the episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003: 47 (3): 1072-1080.
17. Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: a randomized clinical trial of dosing regimens. Dermatol Surg 2000: 26 (1): 50-54.
18. Spruance SL, Rowe NH, Raborn GW, et al. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: a double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis 1999: 179 (2): 303-310.
19. Wall SH, Ramey SJ, Wall F. Famciclovir as antiviral prophylaxis in laser resurfacing procedures. Plast Reconstr Surg 1999: 104: 1103-1108.
20. Arvin AM, Prober CG. Herpes simplex virus type 2 - a persistent problem. N Engl J Med 1997: 337: 1158-1159.
21. Beutner KR, Geisse JK. Imiquimod - an Immune response modifier for the treatment of genital warts. Today's Therapeutic Trends 1997: 15 (3): 165-178.
22. Crumpacker CS. Use of antiviral drugs to prevent herpes virus transmission. N Engl J Med 2004: 350: 67-68.
23. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 United States, 1976 to 1994. N Engl J Med 1997: 337: 1105-1111.
24. Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999: 341 (19): 1432-1438.
25. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992: 116: 197-202.
26. Reynolds SJ, Risbud AR, Shepherd M, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003 May 15: 187 (10): 1513-1521.
27. Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998: 280: 61-66.
28. Slomka MJ. Current diagnostic techniques in genital herpes: their role in controlling the epidemic. Clin Laboratory 2000: 46 (11-12): 591-607.
29. Villa A, Berman B. Genital herpes infection: beyond a clinical diagnosis. Skinmed 2003 March - April: 2 (2): 108-112.
30. Morrow AR, Friedrich D. Inaccuracy of certain enzyme immunoassays in diagnosing genital infections with herpes simplex virus types 1 or 2. Am J Clin Pathol 2003: 120 (6): 839-844.
31. Ribes JA, Hayes M, Smith A. Comparative performance of herpes simplex virus type 2-specific serologic assays from Meridian Diagnostics and MRL Diagnostics. J Clin Microbiol 2001: 39: 3740-3742.
32. Turner KR, Wong EH, Kent CK. Serologic herpes testing in the real world. Sex Transm Dis 2002: 29: 422-425.
33. Lin P, Torres G, Tyring SK. Changing paradigms in dermatology: antivirals in dermatology. Clin Dermatol 2003: 21 (5): 426-446.
34. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003: 163: 76-80.
35. Safrin S, Assaykeen T, Follansbee H, et al. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990: 161 (6): 1078-1084.
36. Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997: 176 (4): 892-898.
37. Romanowski B, Marina RB, Roberts JN. Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis 2003 March: 30 (3): 226-231.
38. Reitano M, Tyring S, Lang W et al. Valacyclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valacyclovir HSV Study Group. J Infect Dis 1998: 178 (3): 603-610.
39. Tyring SK, Diaz-Mitoma F, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials. J Cutan Med Surg 2003: 7 (6): 449-454.
40. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Eng J Med 2004: 350(1): 11-20.
41. Wald A, Langenberg AGM, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001: 285: 3100-3106.
42. Sheffield JS, Hollier LM, Hill JB, et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol 2003: 102 (6): 1396-1403.
43. Spruance SL, Tyring SK, Smith MH, et al. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis 2001: 184 (2): 196-200.
44. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-d - adjuvant vaccine to prevent genital herpes. N Engl J Med 2002: 347: 1652-1661.
45. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science 1999: 283: 1277-1278.
46. Stanberry LR, Cunningham AL, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000: 30: 549-566.
47. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group JAMA 1999: 282 (4): 331-340.
48. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, et al. Medical progress: neurologic complications reactivation varicella-zoster virus. N Engl J Med 2000: 342: 635-645.
49. Mahalingam R, Wellish M, Wolf W, et al. Latent varicella-zoster virus DNA in human trigeminal and thoracic ganglia. N Engl J Med 1990: 323: 627-631.
50. Clarke P, Beer T, Cohrs R, et al. Configuration of latent varicella-zoster virus DNA. J Virol 1995: 69: 8151-8154.
51. Klassen TP, Belseck EM, Wiebe N, et al. Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database Syst Rev 2002: 4: CD002980.
52. Aebi C, Ahmed A, Ramilo O. Bacterial complications of primary varicella in children. Clin Infect Dis 1996: 23: 698-705.
53. Monto AS. The disappearance of Reye's syndrome - a public health triumph. N Engl J Med 1999: 340: 1423-1424.
54. Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002: 186 (Suppl. 1): S91-S98.
55. Smego RA, Asperilla MO. Use of acyclovir for varicella pneumonia during pregnancy. Obstet Gynecol 1991: 78: 1112-1116.
56. Vazquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001: 344: 955-960.
57. Seward J, Peterson C, Mascola L, et al. Decline in varicella disease: evidence of vaccine impact. Pediatr Res 2000: 47 (Suppl.): 276A-276A.
58. Burgoon CF Jr, Burgoon JS, Baldridge GD. The natural history of herpes zoster. JAMA: 164: 265-269.
59. Max MB, Schafer SC, Culnane M, Dubner R, Gracely RH. Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther 1988: 43: 363-371.
60. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982: 32: 671-673.
61. Watson CPN, Evans RJ. A comparative trial of amitriptyline and zimeldine in post-herpetic neuralgia. Pain 1985: 23: 387-394.
62. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988: 38: 1427-1432.
63. Gnann JW Jr, Whitley RJ. Herpes Zoster. N Engl J Med 2002: 347: 340-346.
64. Huff JC, Bean B, Balfour HH, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988: 85 (Suppl. 2A): 84-88.
65. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J 1986: 293: 1529-1532.
66. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995: 39: 1546-1553.
67. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995: 123: 89-96.
68. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy or herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000: 9: 863-869.
69. Stacey BR, Glanzman RL. Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. Clin Ther 2003: 25 (10): 2597-2608.
70. Watson CPN, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993: 15: 510-526.
71. Kost RG, Straus SE. Drug therapy: postherpetic neuralgia - pathogenesis, treatment and prevention. N Engl J Med 1996: 335: 32-42.
72. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996: 125 (5): 376-383.
73. Brentjens MH, Torres G, He J, et al. Reduction of postherpetic neuralgia: a study of the effects of gabapentin with valacyclovir during acute zoster outbreaks. San Francisco: American Academy of Dermatology meeting, 2003, abstract.
74. Cohen JI. Medical progress: Epstein-Barr virus infection. N Engl J Med 2000: 343: 481-492.
75. Papesch M, Watkins R. Epstein-Barr virus infectious mononucleosis. Clin Otolaryngol 2001: 26 (1): 3-8.
76. Davis JE, Moss DJ. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Tissue Antigens 2004: 63 (4): 285-292.
77. Pitetti RD, Laus S, Wadowsky RM. Clinical evaluation of a quantitative real time polymerase chain reaction assay for diagnosis of primary Epstein-Barr virus infection in children. Pediatr Infect Dis J 2003: 22 (8): 736-739.
78. van der Horst C, Joncas J, Ahronheim G, et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis 1991: 164 (4): 788-792.
79. Roy M, Bailey B, Amre DK, et al. Dexamethasone for the treatment of sore throat in children with suspected infectious mononucleosis: a randomized, double-blind, placebo-controlled, clinical trial. Arch Pediatr Adolesc Med 2004: 158 (3): 250-254.
80. Tynell E, Aurelius E, Brandell A, et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J Infect Dis 1996: 174: 324-331.
81. Maki DG, Reich RM. Infectious mononucleosis in the athlete: diagnosis, complications and management. Am J Sports Med 1982: 10 (3): 162-173.
82. Milpied N, Antoine C, Garnier JL, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in B post-transplant lymphoproliferative disorders (B PTLDs): a retrospective analysis of 32 patients. Ann Oncol 1999: 10 (Suppl. 3): 5-5. (Abstract).
83. Keilholz U, Szelenyi H, Siehl J, et al. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 monoclonal antibody) and interleukin-2. Leuk Lymphoma 1999: 35: 641-642.
84. Roskrow MA, Suzuki N, Can Y-J, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998: 91: 2925-2934.
85. Gu S-Y, Huang T-M, Ruan L, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995: 84: 171-177.
86. Jackman WT, Mann KA, Hoffmann HJ, Spaete RR. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for EBV subunit vaccine. Vaccine 1999: 17: 660-668.
87. Landolfo S, Gariglio M, Gribaudo G, et al. The human cytomegalovirus. Pharmacol & Therapeutics 2003: 98 (3): 269-297.
88. Gerna G, Zipeto D, Parea M, et al. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. J Infect Dis 1991: 164: 488-498.
89. Bowen EF, Sabin CA, Wilson P. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 1997: 11: 889-893.
90. Crumpacker CS. Drug therapy: ganciclovir. N Engl J Med 1996: 335: 721-729.
91. Martin JC, Dvorak CA, Smee DF, Matthews TR, Verheyden JPH. 9-[(1,3- Dihydroxy-2-propoxy) methyl]guanine: a new potent and selective antiherpes agent. J Med Chem 1983: 26: 759-761.
92. Sullivan V, Talarico CL, Stanat SC, et al. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992: 358: 162-164.
93. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995: 333: 615-620.
94. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996: 334: 1491-1497.
95. Lowance D, Neumayer H-H, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999: 340: 1462-1470.
96. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994: 112: 1531-1539.
97. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988: 109: 777-782.
98. Schmidt GM, Kovacs A, Zaia JA, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988: 46: 905-907.
99. Lalezari JP, Friedberg DN, Bisset J, et al. High-dose oral ganciclovir treatment for cytomegalovirus retinitis. J Clin Virol 2002: 24: 79-84.
100. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999: 39: 800-804.
101. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002: 346: 1119-1126.
102. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992: 326: 213-220.
103. The Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy versus monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the cytomegalovirus retreatment trial. Arch Ophthalmol 1996: 114: 23-33.
104. Dieterich DT, Poles MA, Lew EA, et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1993: 167: 1184-1188.
105. Lalezari J, Holland G, Stagg R, et al. A randomized, controlled study of cidofovir (CDV) for relapsing cytomegalovirus retinitis (CMV-R) inpatients with AIDS. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco 1995 September 17-20. Washington, D.C.: American Society of Microbiology, 1995. abstract.
106. Detrick B, Nagineni CN, Grillone LR, et al. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides. Invest Ophthalmol Vis Sci 2001: 42: 163-169.
107. VITRAVENESTUDYGROUP. A randomized, controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Opthalmol 2002: 133: 484-498.
108. Hall CB, Long CE, Schnabel KC, et al. Human herpes virus-6 infection in children - a prospective study of complications and reactivation. N Engl J Med 1994: 331: 432-438.
109. Arsenault S, Gravel A, Gosselin I, et al. Generation and characterization of a monoclonal antibody specific for human herpes virus 6 variant A immediate-early 2 protein. J Clin Virol 2003: 28 (3): 284-290.
110. De Bolle L, Andrei G, Snoeck R, et al. Potent, selective and cell-mediated inhibition of human herpes virus 6 at an early stage of viral replication by the non-nucleoside compound CMV423. Biochem Pharmacol 2004: 67 (2): 325-336.
111. Leach CT. Human herpes virus-6 and -7 infections in children: agents of roseola and other syndromes. Curr Opin Pediatr 2000: 12 (3): 269-274.
112. Burns WH, Sandford GR. Susceptibility of human herpes virus 6 to antivirals in vitro. J Infect Dis 1990: 162 (3): 634-637.
113. Wyatt LS, Rodriguez WJ, Balachandran N, et al. Human herpes virus 7: antigenic properties and prevalence in children and adults. J Virol 1991: 65: 6260-6265.
114. Black JB, Inoue N, Kite-Powell K, et al. Frequent isolation of human herpes 7 from saliva. Virus Res 1993: 29: 91-98.
115. Wilborn F, Schmidt CA, Lorenz F, et al. Human herpes-virus type 7 in blood donors: detection by the polymerase chain reaction. J Med Virol 1995: 47: 65-69.
116. Chan PK, Peiris JS, Yuen KY, et al. Human herpes virus-6 and human herpes virus-7 infections in bone marrow suppressed recipients. J Med Virol 1997: 53: 295-305.
117. Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpes virus 8 infection. N Engl J Med 1998: 338: 948-954.
118. Smith NA, Sabin CA, Gopal R, et al. Serologic evidence of human herpes virus 8 transmission by homosexual but not heterosexual sex. J Infect Dis 1999: 180: 600-606.
119. Bourboulia D, Whitby D, Boshoff C, et al. Serologic evidence for mother-to-child transmission of Kaposi's sarcoma-associated herpes virus infection. JAMA 1998: 280: 31-32.
120. Curreli F, Robles MA, Friedman-Kien AE, et al. Detection and quantitation of Kaposi's sarcoma-associated herpes-virus (KSHV) by a single competitive-quantitative polymerase chain reaction. J Virol Meth 2003: 107 (2): 261-267.
121. Robin YM, Guillou L, Michels JJ, et al. Human herpes virus 8 immunostaining: a sensitive and specific method for diagnosing Kaposi sarcoma in paraffin-embedded sections. Am J Clin Pathol 2004: 121 (3): 330-334.
122. Jones JL, Hanson DL, Dworkin MS, et al. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000: 24 (3): 270-274.
123. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. BMJ 1999: 319: 23-24.
124. Ambinder RF. Viruses as potential targets for therapy in HIV-associated malignancies. Hematol Oncol Clin North Am 2003: 17 (3): 697-702.
125. Morini M, Albini A, Lorusso G, et al. Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immunogène therapy. Gene Ther 2004: 11 (3): 284-291.
126. De Wit R, Schattenkerk JK, Boucher CA, et al. Clinical and virologic effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet 1988: 2: 1214-1217.
127. Abrams DI, Volberding PA. Alpha-interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol 1987: 4 (Suppl. 2): 43-47.
128. Aboulafia DM, Norris D, Henry D, et al. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch Dermatol 2003: 139 (2): 178-186.
129. Duvic M, Friedman-Kien AE, Looney DJ, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Arch Dermatol 2000: 136 (12): 1544-1546.
130. Dhar AD, Werchniak AE, Li Y, et al. Brief Report: tanapox infection of a college student. N Engl J Med 2004: 350: 361-366.
131. Croitoru AG, Birge MB, Rudikoff D, et al. Tanapox virus infection. Skinmed 2002: 1: 156.
132. Knight JC, Novembre FJ, Brown DR, et al. Studies on tanapox virus. Virology 1989: 172: 116-124.
133. Reed KD, Melski JW, Graham MB, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 2004: 350: 342-350.
134. Anderson MG, Frenkel LD, Homann S, et al. A case of severe monkeypox virus disease in an American child: emerging infections and changing professional values. Pediatr Infect Dis J 2003: 22 (12): 1093-1096.
135. Frey SE, Belshe RB. Poxvirus zoonoses - putting pocks into context. N Engl J Med 2004: 350 (4): 342-350.
136. Interim guidance for collection of diagnostic specimens from persons with suspect monkeypox. Atlanta: Centers for Disease Control and Prevention, June 23, 2003. (http:// www.cdc.gov/ncidod/monkeypox/diagspecimens.htm).
137. Zaucha GM, Jahrling PB, Geisbert TW, et al. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis) Laboratory Invest 2001: 81: 1581-1600.
138. Sepkowitz KA. Current concepts: how contagious is vaccinia? N Engl J Med 2003: 348: 439-446.
139. Grabenstein JD, Winkenwerder W. US military smallpox vaccination program experience. JAMA 2003: 289: 3278-3282.
140. Bicknell WJ. The case for voluntary smallpox vaccination. N Engl J Med 2002: 346: 1323-1325.
141. Thorne CD, Hirshon JM, Himes CD, et al. Emergency medicine tools to manage smallpox (vaccinia) vaccination complications: clinical practice guideline and policies and procedures. Ann Emerg Med 2003: 42 (5): 665-680.
142. Quenelle DC, Collins DJ, Kern ER. Efficacy of multiple or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother 2003: 47 (10): 3275-3280.
143. Smee DF, Sidwell RW. A review of compounds exhibiting anti-Orthopoxvirus activity in animal models. Antiviral Res 2003: 57 (1-2): 41-52.
144. Meadows KP, Tyring SK, Pavia AT, et al. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 1997: 133 (8): 987-990.
145. Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res 2003: 58(2): 101-114.
146. Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003: 25; 289 (24): 3283-3289.
147. Eyler JM. Smallpox in history: the birth, death, and impact of a dread disease. J Laboratory Clin Med 2003: 142 (4): 216-220.
148. Guharoy R, Panzik R, Noviasky IA, et al. Smallpox: clinical features, prevention, and management. Ann Pharmacother 2004: 38 (3): 440-447.
149. Breman JG, Henderson DA. Current concepts manage smallpox. N Engl J Med 2002: 346 (17): 1300-1308.
150. Bray M, Buller M. Looking back at smallpox. Clin Infect Dis 2004: 15: 38 (6): 882-889.
151. Keith KA, Hitchcock MJ, Lee WA, et al. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of Orthopoxvirus replication. Antimicrob Agents Chemother 2003: 47 (7): 2193-2198.
152. Roy CJ, Baker R, Washburn K, et al. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Antimicrob Agents Chemother 2003: 47 (9): 2933-2937.
153. Rosenthal SR, Merchlinsky M, Kleppinger C, et al. Development of new smallpox vaccines. Emerg Infect Dis 2001: 7 (6): 920-926.
154. Torfason EG, Gunadottir S. Polymerase chain reaction for laboratory diagnosis of orf virus infections. J Clin Virol 2002: 24 (1-2): 79-84.
155. Nettleton PF, Brebner I, Pow I, et al. Tissue culture-propagated orf virus vaccine protects lambs from orf virus challenge. Vet Rec 1996: 138 (8): 184-186.
156. Konya I, Thompson CH. Molluscum contagiosum virus: antibody responses in persons with clinical lesions and seroepidemiology in a representative Australian population. J Infect Dis 1999: 179 (3): 701-704.
157. Bugert JJ, Melquiot N, Kehm R. Molluscum contagiosum virus expresses late genes in primary human fibroblasts but does not produce infectious progeny. Virus Genes 2001: 22 (1): 27-33.
158. Thompson CH. Identification and typing of molluscum contagiosum virus in clinical specimens by polymerase chain reaction. J Med Virol 1997: 53 (3): 205-211.
159. Nunez A, Funes JM, Agromayor M, et al. Detection and typing of molluscum contagiosum virus in skin lesions by using a simple lysis method and polymerase chain reaction. J Med Virol 1996: 50 (4): 342-349.
160. Ohkuma M. Molluscum contagiosum treated with iodine solution and salicylic acid plaster. Int J Dermatol 1990: 29 (6): 443-445.
161. Gon VK, Longstaff E. Podophyllin office therapy against condyloma should be abandoned. Sex Transm Infect 2001: 77: 409-412.
162. Bayerl C, Feller G, Goerdt S. Experience in treating molluscum contagiosum in children with imiquimod 5% cream. Br J Dermatol 2003: 149 (Suppl. 66): 25-29.
163. Ross GL, Orchard DC. Combination topical treatment of molluscum contagiosum with cantharidin and imiquimod 5% in children: a case series of 16 patients. Australas J Dermatol 2004: 45 (2): 100-102.
164. Strauss RM, Doyle EL, Mohsen AH, et al. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient. Int J STD AIDS 2001: 12 (4): 264-266.
165. Brown CW Jr, O'Donoghue M, Moore J, et al. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod. Cutis 2000: 65 (6): 363-366.
166. Calista D. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. J Eur Acad Dermatol Venereol 2000: 14 (6): 484-488.
167. Davies EG, Thrasher A, Lacey K, et al. Topical cidofovir for severe molluscum contagiosum [letter]. Lancet 1999: 353 (9169): 2042.
168. Cunha BA. Smallpox and measles: historical aspects and clinical differentiation. Infect Dis Clin North Am 2004: 18 (1): 79-100.
169. Gellin BG, Katz SL. Putting a stop to a serial killer: measles. J Infect Dis 1994: 170 (Suppl. 1): 51-52.
170. Moss WJ, Monze M, Ryon JJ, et al. Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis 2002: 35 (2): 189-196.
171. Helfand RF, Chibi T, Biellik R, et al. Negative impact of clinical misdiagnosis of measles on health workers' confidence in measles vaccine. Epidemiol Infect 2004: 132 (1): 7-10.
172. Chakravarti A, Rawat D, Yadav S. Whole blood samples as an alternative to serum for detection of immunity to measles virus by ELISA. Diagn Microbiol Infect Dis 2003: 47 (4): 563-567.
173. Ozoemena LC, Minor PD, Afzal MA. Comparative evaluation of measles virus specific TaqMan PCR and conventional PCR using synthetic and natural RNA templates. J Med Virol 2004: 73 (1): 79-84.
174. Kaplan LJ, Daum RS, Smaron M, et al. Severe measles in immunocompromised patients. JAMA 1992: 267 (9): 1237-1241.
175. Tomoda A, Nomura K, Shiraishi S, et al. Trial of intraventricular ribavirin therapy for subacute sclerosing panencephalitis (SSPE) in Japan. Brain Dev 2003: 25 (7): 514-517.
176. D'Souza RM, D'Souza R. Vitamin A for the treatment of children with measles - a systematic review. J Trop Pediatr 2002: 48 (6): 323-327.
177. Duke T, Mgone CS. Measles: not just another viral exanthem. Lancet 2003: 361 (9359): 763-773.
178. Carmena J, Tomero C, Salcedo M, et al. Pneumonia caused by measles in a pregnant woman with HIV antibodies: response to treatment with immunoglobulins. Enfermedades Infecciosas y Microbiologia Clinica 1996: 14: 456-457.
179. Rice P, Young Y, Cohen B, et al. MMR immunization after contact with measles virus. Lancet 2004: 363 (9408): 569-570.
180. Atkinson WL, Orenstein WA. The resurgence of measles in the United States, 1989-1990. Annu Rev Med 1992: 43: 451-463.
181. Centers for Disease Control (CDC). Measles outbreak in a boarding school - Pennsylvania. MMWR Morb Mortal Wkly Report 2004: 53 (14): 306-309.
182. Centers for Disease Control (CDC). Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR Morb Mortal Wkly Rep 1997: 46: 1-20.
183. Samuel D, Beard S, Yang H, et al. Genotyping of measles and mumps virus strains using amplification refractory mutation system analysis combined with enzyme immunoassay: a simple method for outbreak investigations. J Med Virol 2003: 69 (2): 279-285.
184. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mums, and rubella vaccination and autism. N Engl J Med 2002: 347: 1477-1482.
185. Sugg WC, Finger JA, Levine RH, et al. Field evaluation of live virus mumps vaccination. J Pediatr, 1968: 72: 461-466.
186. Hilleman RE, Buynak EB, Weibel RE, et al. Live, attenuated mumps vaccine. N Engl J Med 1968: 278: 227-232.
187. Jonville-Bera AP, Autret E, Galy-Eyraud C, et al. Aseptic meningitis following mumps vaccine: a retrospective survey by the French Regional Pharmacovigilance centers and by Pasteur-Merieux Serums & vaccines. Pharmacoepidemiol Drug Saf 1996: 5 (1): 33-37.
188. Revello MG, Baldanti F, Sarasini A, et al. Prenatal diagnosis of rubella virus infection by direct detection and semiquantitation of viral RNA in clinical samples by reverse transcription-PCR. J Clin Microbiol 1997: 35 (3): 708-713.
189. Tang JW, Aarons E, Hesketh LM, et al. Prenatal diagnosis of congenital rubella infection in the second trimester of pregnancy. Prenat Diagn 2003: 23 (6): 509-512.
190. Banatvala JE, Brown DW. Rubella. Lancet 2004: 363 (9415): 1127-1137.
191. Vyse AJ, Jin L. An RT-PCR assay using oral fluid samples to detect
192. Giessauf A, Letschka T, Walder G, et al. A synthetic peptide ELISA for the screening of rubella virus neutralizing antibodies in order to ascertain immunity. J Immunol Meth 2004: 287 (1-2): 1-11.
193. Reef SE, Frey TK, Theall K, et al. The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention. JAMA 2002: 287: 464-472.
194. Zerbini M, Gallinella G, Cricca M, et al. Diagnostic procedures in B19 infection. Pathol Biol (Paris) 2002: 50 (5): 332-338.
195. Young NS, Brown KE. Mechanisms of disease. Parvovirus B19 N Engl J Med 2004: 350 (6): 586-597.
196. Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989: 321 (8): 519-523.
197. Frickhofen N, Abkowitz J, Safford M, et al. Persistent parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990: 113 (12): 926-933.
198. Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003: 187 (4): 675-678.
199. Erensoy S, Bilgic A, Arda B, et al. Low-dose intramuscular hepatitis B vaccination in medical students: 4-year follow-up. Infection 2002: 30 (5): 303-305.
200. Protection against viral hepatitis: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1990: 39: 17-22.
201. Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol 2004: 11 (1): 18-25.
202. Lee WM. Medical progress: hepatitis B virus infection. N Engl J Med 1997: 337 (11): 1733-1745.
203. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988: 95: 1318-1325.
204. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991: 114: 629-634.
205. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996: 334 (22): 1422-1427.
206. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993: 119 (4): 312-323.
207. Lai C-L, Chien R-N, Leung NWY, et al. A one-year trial lamivudine for chronic hepatitis B. N Engl J Med 1998: 339: 61-68.
208. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003: 348 (9): 808-816.
209. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003: 348 (2): 177-178.
210. Lemon SM, Thomas DL. Drug therapy: vaccines to prevent viral hepatitis. N Engl J Med 1997: 336 (3): 196-204.
211. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980: 303 (15): 833-841.
212. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982: 307: 1481-1486.
213. Chang M-H, Chen C-J, Lai M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular Carcinoma in children. N Engl J Med 1997: 336 (26): 1855-1859.
214. Pawlotsky JM. Use and interpretation of hepatitis C virus diagnostic assays. Clin Liver Dis 2003: 7 (1): 127-137.
215. Grant PR, Sims CM, Tedder RS. Quantification of HCV RNA levels and detection of core antigen in donations before seroconversion. Transfusion 2002: 42 (8): 1032-1036.
216. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989: 321 (22): 1501-1506.
217. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo- controlled trial. N Engl J Med 1989: 321 (122): 1506-1510.
218. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339 (21): 1485-1492.
219. Zeuzem S, Feinman Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000: 343 (23): 1666-1672.
220. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002: 36 (5 Suppl. 1): S121-S127.